RELIEF THERAPEUTICS S/ADR - RLFTY STOCK NEWS

Relief Therapeutics has launched PKU GOLIKE in the U.S., a medical food for managing phenylketonuria (PKU). This launch, aided by an exclusive distributor, fulfills a milestone from the acquisition of APR Applied Pharma Research. Relief will make a milestone payment of CHF 2.8 million and issue 150 million shares, increasing its treasury by 200 million shares. Approximately 20,000 PKU patients in the U.S. require this dietary supplement for metabolic management. PKU GOLIKE offers improved patient compliance with its unique formulation, previously available in the E.U. since 2019.

Relief Therapeutics has appointed a leading national health services company as the exclusive distributor of PKU GOLIKE in the U.S. This product is a next-generation medical food developed for managing phenylketonuria (PKU) using patented Physiomimic™ technology, aimed at enhancing patient compliance. In 2023, the company plans to file for approval of APR-OD032, expanding its offerings for PKU treatment. The collaboration boosts the company's market approach and aims to improve patient access to innovative dietary solutions.

Relief Therapeutics has announced the initiation of an Investigator Initiated Trial for Nexodyn to address Epidermolysis Bullosa (EB), a rare skin condition affecting about 250,000 patients globally. The trial, approved by the IRB, will be led by Professor Amy Paller at a Chicago hospital, enrolling 15 participants over 12 weeks. This trial aims to evaluate the effectiveness of APR-TD011, a hypochlorous acid topical spray, in managing EB wounds. Positive outcomes could lead to FDA and EMA approvals, enhancing treatment options for EB patients.

Relief Therapeutics announced its half-year results for 2022, reporting revenues of CHF 3.24 million from product sales, licensing fees, and royalties. The company anticipates the U.S. launch of PKU GOLIKE in Q4 2022, following the acquisition of commercialization rights for a new dosage form of a prescription drug for PKU. The FDA accepted the NDA for ACER-001 with a decision expected by January 15, 2023. However, the company incurred a net loss of CHF 26.5 million, driven by increased expenses and an impairment charge of CHF 8.2 million on intangible assets.

Relief Therapeutics, a Swiss biopharmaceutical company focused on rare diseases, announced participation in the 22nd Annual Biotech in Europe Forum on September 21-22, 2022, in Basel, Switzerland. CFO Jack Weinstein will lead a panel discussion titled Navigating Global Capital Markets in Current Times on September 21 at 1:35 pm CEST, followed by a company presentation at 3:20 pm CEST. The company engages with institutional investors and offers one-on-one meetings during the event. Relief develops innovative treatments for conditions like PKU and pulmonary disorders.

Relief Therapeutics announced that Jack Weinstein, the Chief Financial Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference scheduled for September 13, 2022, at 1:30 PM ET. The event runs from September 12-14, 2022, where management will conduct one-on-one meetings with registered institutional investors. A live webcast of the presentation will be available on Relief’s website and archived for 90 days. Relief focuses on developing treatments for rare diseases and has ongoing collaborations and product pipelines addressing significant unmet medical needs.

Relief Therapeutics has filed a Registration Statement on Form F-1 with the U.S. SEC for a proposed offering of its ordinary shares as American Depositary Shares (ADSs). The details including the number of ADSs and pricing are yet to be determined. Relief aims to list its ADSs on the NASDAQ under the symbol RLFT. However, completion of the offering and listing success are uncertain. Relief operates in rare diseases and has a collaboration with Acer Therapeutics for metabolic disorders.

Relief Therapeutics Holding SA and NRx Pharmaceuticals announced a tentative settlement regarding their pending litigation. The parties will collaborate to finalize this settlement within 30 days and have agreed to a 60-day extension to negotiate the definitive settlement agreement. The settlement may involve a re-allocation of development rights and licensing for aviptadil, although success is not guaranteed. Investors are advised that uncertainties remain regarding the completion of the settlement.

Relief Therapeutics has appointed David McCullough as the Senior Director and Head of U.S. Market Access, effective August 22, 2022. This newly created role is aimed at enhancing market access strategies for the company's products. McCullough brings over 20 years of experience from various biopharmaceutical companies, including Mirum Pharmaceuticals and Novartis Gene Therapies. His expertise will be pivotal as Relief prepares for the October 2022 launch of PKU GOLIKE. This appointment signifies a milestone in Relief's growth and commitment to patient access.